Drug Trial Radar · NCT05665595
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,594
Actual
Start
Jan 19, 2023
Primary completion
Mar 6, 2024
Study completion Sep 24, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Dec 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS). The primary hypothesis is that pembrolizumab/vibostolimab is superior to pembrolizumab with respect to RFS as assessed by the investigator in participants with high-risk resected Stage IIB, IIC, III and IV melanoma.
Conditions
- Melanoma
Interventions
Pembrolizumab/VibostolimabBiological
Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 17 administrations
PembrolizumabBiological
Pembrolizumab 25 mg/mL administered as IV infusion for up to 17 administrations
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recurrence-Free Survival (RFS)Time frame: Up to approximately 13 months
Locations
205 sites in 26 countries. Site status is shown where the registry gives one.
Moores Cancer Center ( Site 0116)
La Jolla, California
The Angeles Clinic and Research Institute - West Los Angeles Office ( Site 0123)
Los Angeles, California
UCLA Hematology/Oncology - Westwood (Building 100) ( Site 0131)
Los Angeles, California
California Pacific Medical Center - Pacific Campus ( Site 0111)
San Francisco, California
UCSF Medical Center at Mission Bay ( Site 0130)
San Francisco, California
The Melanoma & Skin Cancer Institute ( Site 0120)
Englewood, Colorado
Georgetown University Medical Center ( Site 0144)
Washington D.C., District of Columbia
University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0110)
Miami, Florida
Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center ( Site 0124)
Tampa, Florida
Northwestern Memorial Hospital ( Site 0109)
Chicago, Illinois
Advocate Medical Group-Oncology ( Site 0102)
Park Ridge, Illinois
University of Iowa-Holden Comprehensive Cancer Center ( Site 0107)
Iowa City, Iowa
Henry Ford Hospital ( Site 0133)
Detroit, Michigan
Comprehensive Cancer Centers of Nevada ( Site 0142)
Las Vegas, Nevada
R.J. Zuckerberg Cancer Center-Medical Oncology ( Site 0132)
Lake Success, New York
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0146)
Mineola, New York
Laura and Isaac Perlmutter Cancer Center-Hematology and Oncology ( Site 0113)
New York, New York
Icahn School of Medicine at Mount Sinai ( Site 0118)
New York, New York
Weill Cornell Medical College ( Site 0115)
New York, New York
Levine Cancer Institute ( Site 0138)
Charlotte, North Carolina
Sanford Fargo Medical Center ( Site 0127)
Fargo, North Dakota
Children's Hospital of Pittsburgh ( Site 0141)
Pittsburgh, Pennsylvania
UPMC Hillman Cancer Center ( Site 0135)
Pittsburgh, Pennsylvania
Sanford Cancer Center ( Site 0125)
Sioux Falls, South Dakota
The West Clinic, PLLC dba West Cancer Center ( Site 0119)
Germantown, Tennessee
St. Jude Children's Research Hospital ( Site 0106)
Memphis, Tennessee
Vanderbilt University Medical Center ( Site 0139)
Nashville, Tennessee
University of Texas MD Anderson Cancer Center ( Site 0145)
Houston, Texas
Inova Schar Cancer Institute ( Site 0103)
Fairfax, Virginia
University of Wisconsin Hospital and Clinics ( Site 0108)
Madison, Wisconsin
Sanatorio Finochietto ( Site 0212)
Buenos Aires, Argentina
Clinica Adventista Belgrano-Oncology ( Site 0211)
CABA, Argentina
Centro de Investigaciones Metabólicas (CINME)-Oncology ( Site 0204)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Instituto Alexander Fleming-Alexander Fleming ( Site 0209)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0200)
Buenos Aires, Buenos Aires F.D., Argentina
Instituto de Oncología de Rosario ( Site 0206)
Rosario, Santa Fe Province, Argentina
Blacktown Hospital-Blacktown Cancer and Haematology Centre - Medical Oncology ( Site 1464)
Blacktown, New South Wales, Australia
Calvary Mater Newcastle-Medical Oncology ( Site 1462)
Waratah, New South Wales, Australia
Melanoma Institute Australia-Clinical Trials Unit ( Site 1450)
Wollstonecraft, New South Wales, Australia
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si
Brisbane, Queensland, Australia
Showing 40 of 205 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.